StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning
StreetAccount Summary - Trading higher/lower: Asia mid-morning
BioNTech, OncoC4 present data from PRESERVE-003 trial of gotistobart at NACLC 2025 ($99.72, 0.00)
StreetAccount Sector Summary - China Healthcare September Recap
Powered by FactSet Research Systems Inc.